Accueil du site Les Rencontres lyonnaises de Rythmologie.
     
WEDNESDAY MAY 23, 2012 / MERCREDI 23 MAI 2012
   

The speakers reserve the right not to publish their presentation on the website www.isheid.com.
   

Les intervenants du Congrès se réservent le droit d'accepter la mise en ligne de leur présentation
sur le site www.isheid.com.
     
08.45
09.00		    
Alain LAFEUILLADE, General Hospital, Toulon - France Alain LAFEUILLADE, General Hospital, Toulon - France
 

Welcoming Address / Message de Bienvenue
Alain LAFEUILLADE, General Hospital, Toulon - France

   
   
09.00
11.00		  

PREVENTION OF HIV TRANSMISSION / PREVENTION DE LA TRANSMISSION DU VIH

Chairpersons / Modérateurs : Stefano VELLA, Sanitary Superior Institute, Roma - Italy
   
  Patricia ENEL, COREVIH, Marseille - France
Anna Mia EKSTROM, Karolinska Institutet, Stockholm - Sweden Update on HIV Pandemic / Derniers chiffres de la Pandémie VIH
Anna Mia EKSTROM, Karolinska Institutet, Stockholm - Sweden   Anna Mia EKSTROM, Karolinska Institutet, Stockholm - Sweden
Mark WAINBERG, McGill University, Montreal - Canada   Pre-Exposure Prophylaxis Against HIV : Pros and Cons
Mark WAINBERG, McGill University, Montreal - Canada   Prophylaxie Pré-Exposition du VIH : Données et Controverses
    Mark WAINBERG, McGill University, Montreal - Canada
Patients’ Treatment as Prevention / Traiter les Patients pour Prévenir de la Transmission
Joep LANGE, University of Amsterdam - Netherlands Joep LANGE, University of Amsterdam - Netherlands
     
11.30
13.00		  

NEW DRUGS (HIV, HCV) / LES NOUVELLES MOLECULES (VIH, VHC)

Chairpersons / Modérateurs : Caroline SOLAS, Timone’s Hospital, Marseille - France
 
  Giuseppe TAMBUSSI, Vaccine and Immunotherapy Research Center, Milano - Italy
New Antiretrovirals / Nouveaux Antirétroviraux
Roy GULICK, Weill Medical College of Infectious Diseases, New York - USA   Roy GULICK, Weill Medical College of Infectious Diseases, New York - USA
Jean-Michel PAWLOTSKY, Henri Mondor Hospital, Créteil - France New Anti-HCV Drugs / Nouvelles Molécules Anti-VHC
Jean-Michel PAWLOTSKY, Henri Mondor Hospital, Créteil - France   Jean-Michel PAWLOTSKY, Henri Mondor Hospital, Créteil - France
New Drug Interactions in HIV and HCV /Nouvelles Interactions Médicamenteuses dans le VIH et le VHC
David BACK, University of Liverpool - UK   David BACK, University of Liverpool - UK
Susana T. Valente 002 - Potent suppression of HIV viral replication by a novel inhibitor of Tat
    Authors: Guillaume Mousseau (1), Mark A. Clementz (1), Wendy N. Bakeman (1), Nisha Nagarsheth (1),
Michael Cameron (2), Jun Shi (3), Phil Baran (3), Rémi Fromentin (4), Nicolas Chomont (4) and
Susana T. Valente (1)
(1) Department of Infectology, The Scripps Research Institute, Jupiter, Florida, United States
(2) Department of Molecular Therapeutics and Translational Research Institute, The Scripps Research
Institute, Jupiter, Florida, United States
(3) Department of Chemistry, The Scripps Research Institute, La Jolla, California, 4Vaccine and Gene
Therapy Institute, Port St. Lucie, Florida, United States
13.00
14.00		  

SYMPOSIUM SATELLITE Bristol-Myers Squibb
Inflammation and HIV/HCV co-infection / Inflammation et co-infection VIH/VHC

   
Chairpersons / Modérateurs : Pierre-Marie GIRARD, Saint-Antoine Hospital, Paris - France
Auto-immunity and HCV: Recent data in physiopothology and their therapeutical consequences
    Auto-Immunité et VHC : Données Récentes de Physiopathologie et Implication Thérapeutique
    Patrice CACOUB, La Pitié-Salpétrière Hospital, Paris - France
Persistant Immune Activation during HIV/HCV co-infection: A new treatment label?
    Activation Immune Persistante au cours de la Co-Infection VIH/VHC : Une Nouvelle Indication de Traitement ?
    Isabelle POIZOT-MARTIN, Sainte-Marguerite Hospital, Marseille - France
  Debate / Débat
    Pierre-Marie GIRARD, Saint-Antoine Hospital, Paris - France
    Patrice CACOUB, La Pitié-Salpétrière Hospital, Paris - France
    Isabelle POIZOT-MARTIN, Sainte-Marguerite Hospital, Marseille - France
14.00
15.30		  

MANAGING ANTIRETROVIRAL THERAPY PART I /GESTION DES TRAITEMENTS ANTIRETROVIRAUX, PARTIE I

Chairpersons / Modérateurs : José GATELL, Clinique Institute of Medicine & Dermatology, Barcelona - Spain
   
  Isabelle POIZOT-MARTIN, Sainte-Marguerite Hospital, Marseille - France
Salvage Therapy in 2012 /La Thérapie de Sauvetage en 2012
Stefano VELLA, Sanitory Superior Institute, Roma - Italy   Stefano VELLA, Sanitory Superior Institute, Roma - Italy
Managing Antiretrovirals in co-infected Patients in 2012
Juergen ROCKSTROH, University of Bonn - Germany   Gestion des Antirétroviraux chez les Patients Co-infectés VIH/VHC en 2012
    Juergen ROCKSTROH, University of Bonn - Germany
Clinical Use of Pharmacogenomics /Utilité Clinique de la Pharmacogénomique
Amalio TELENTI, University of Lausanne - Switzerland   Amalio TELENTI, University of Lausanne - Switzerland
16.00
17.00		 KEYNOTE LECTURE /CONFERENCE PLENIERE
Gene Therapy to Cure HIV? Prospects and Realities
    Guérir le VIH par la Thérapie Génique ? Perspectives et Réalités
  Timothy Ray BROWN, «The Berlin Patient», California - USA
Gero HÜETTER, Heidelberg University, Württemberg - Germany   Gero HÜETTER, Heidelberg University, Württemberg - Germany
Gero HÜETTER, Heidelberg University, Württemberg - Germany
17.00
18.30
SYMPOSIUM MSD Preparing for the long run: Managing the HIV for long term success
Préparer l’avenir : prise en charge des patients infectés par le VIH pour un succès durable
 Chairpersons / Modérateurs : Alain LAFEUILLADE, General Hospital, Toulon - France
   
  Christine KATLAMA , University Hospital, Paris - France
First line: New Strategies and Long term Outcomes
    Première ligne : Nouvelles Stratégies et Devenir à Long terme
    Jacques REYNES, University Hospital, Montpellier - France
Switch Strategies in Virologically Suppressed Patients. Why, When, and What is the Best strategy for the Patients?
    Stratégies de Changement de Traitement chez les Patients contrôlés. Pourquoi, Quand et Quelle est la Meilleure Stratégie ?
    José GATELL, Clinic Institut of Medicine & Dermatology, Barcelona - Spain
Factors Influencing Adherence-Outcome Relationships
    Facteurs d’Adhérence aux Traitements Antirétroviraux et Résultats à Long Terme
    Jean-Jacques PARIENTI, University Hospital, Caen - France
     
 
     
     
THURSDAY MAY 24, 2012 / JEUDI 24 MAI 2012
   

The speakers reserve the right not to publish their presentation on the website www.isheid.com.
   

Les intervenants du Congrès se réservent le droit d'accepter la mise en ligne de leur présentation
sur le site www.isheid.com.
     
08.30
10.30		  

SEARCHING FOR A HIV CURE /VERS L’ERADICATION DU VIH

Chairpersons / Modérateurs : Alain LAFEUILLADE, General Hospital, Toulon - France
   
  Jacques IZOPET, Laboratory of Virology & INSERM U10 43, Toulouse - France
Guido SILVESTRI, Emory University School of Medicine, Atlanta - USA Animal Models of Functional HIV Cure / Modèles Animaux pour une Guérison Fonctionnelle du VIH
Guido SILVESTRI, Emory University School of Medicine, Atlanta - USA   Guido SILVESTRI, Emory University School of Medicine, Atlanta - USA
Molecular Control of HIV - 1 Postintegration Latency : Implications for Therapeutic Strategies
Contrôle Moléculaire de la Latence Post-Intégrationnelle du VIH-1 : Implications pour les Stratégies Thérapeutiques
Guido SILVESTRI, Emory University School of Medicine, Atlanta - USA   Carine VAN LINT, Gosselies Campus, Charleroi - Belgium
Mario STEVENSON, University of Miami, Leonard M. Miller, Miami - USA A Roadmap to a Cure / Une Feuille de Route pour la Guérison
  Mario STEVENSON, University of Miami, Leonard M. Miller, Miami - USA
Towards a Cure for HIV: a Long Road ahead / Guérir du VIH : un Long Chemin à Parcourir
Tae-Wook CHUN, National Institute of Health, Bethesda - USA   Tae-Wook CHUN, National Institute of Health, Bethesda - USA
Romas Geleziunas 003 - Search for Small Molecule Activators of Latent HIV
Romas Geleziunas   Author: Romas Geleziunas
Co-authors: George Stepan, George Wei, Helen Yu, Michael Graupe, Nikos Pagratis, Tiffany Barnes,
Tomas Cihlar, Joe Hesselgesser
Gilead Sciences, Inc., Foster City - USA
11.00
12.30		  

HUMAN RIGHTS & ACCESS TO HIV CARE / DROITS DE L’HOMME ET ACCES AUX SOINS VIH

Under the auspices of /Avec le parrainage de l’ANRS

Chairpersons / Modérateurs : Jean-François DELFRAISSY, General Hospital of Bicêtre, Kremlin-Bicêtre - France
   
  Bruno SPIRE, Inserm & AIDES’ Association Chairman, Marseille - France
Yves SOUTEYRAND, HIV / AIDS Department World Health Organization, Geneva - Switzerland Universal Access to anti-HIV Therapy / Accès Universel à la Thérapie anti-VIH
Yves SOUTEYRAND, HIV / AIDS Department World Health Organization, Geneva - Switzerland   Yves SOUTEYRAND, HIV / AIDS Department World Health Organization, Geneva - Switzerland
Yazdan YAZDANPANAH, Hospital of Bichat, Paris - France Cost-effectiveness in HIV Care / Rapports Coût-Efficacité dans le Traitement du VIH
Yazdan YAZDANPANAH, Hospital of Bichat, Paris - France Yazdan YAZDANPANAH, Hospital of Bichat, Paris - France
     
12.30
14.00		  

LUNCH SYMPOSIUM JANSSEN
HIV, HCV: Friends or Ennemies? / VIH,VHC : Amis ou ennemis ?

Chairpersons / Modérateurs : Jean-Michel MOLINA, Saint-Louis Hospital, Paris - France
HCV is NOT HIV! / Le VHC n’est pas le VIH !
    Jean-Michel PAWLOTSKY , Henri Mondor Hospital, Créteil - France
HCV/HIV: Double trouble / VHC/VIH : Problème double
    Mark NELSON, Chelsea and Westminster Hospital, London - UK
14.00
15.30		  

PRIMARY HIV INFECTION & HIV RESERVOIRS / PRIMO-INFECTION ET RESERVOIRS DU VIH

Chairpersons / Modérateurs : Sabine KINLOCH, The Royal Free Hospital, London - UK
  Magnus GISSLEN, University of Gothenburg - Sweden
Primary HIV infection: The French Experience / Primo-Infection du VIH : l’Expérience Française
Cécile GOUJARD, General Hospital of Bicêtre, Kremlin-Bicêtre - France   Cécile GOUJARD, General Hospital of Bicêtre, Kremlin-Bicêtre - France
Treating since the Beginning? / Faut-il Traiter dès le Début ?
  Jean-Pierre ROUTY, McGill University, Montreal - Canada
Joseph WONG, S an Fransisco VA Medical Center, California - USA Update on HIV Persistence during ART / Mises à Jour de la Persistance du VIH sous Traitement
Joseph WONG, S an Fransisco VA Medical Center, California - USA   Joseph WONG, S an Fransisco VA Medical Center, California - USA
Alain LAFEUILLADE, General Hospital, Toulon - France Anti-latency Agents to Purge HIV Reservoirs / Agents Anti-latence pour Purger les Réservoirs VIH
Alain LAFEUILLADE, General Hospital, Toulon - France   Alain LAFEUILLADE, General Hospital, Toulon - France
Tokameh Mahmoudi 004 - New Transcription Regulatory Mechanisms of Latent HIV LTR
Tokameh Mahmoudi   Authors: Haleh Rafati (1), Yuri Moshkin (1) and Tokameh Mahmoudi (1)
(1) Department of Biochemistry, Erasmus University Medical Centre, Rotterdam, The Netherlands
Co-authors: Maribel Parra (2), Shweta Hakre (3) and Eric Verdin (3)
(2) Cancer Epigenetics and Biology Program (PEBC), IDIBELL, Barcelona, Spain
(3) Gladstone Institute of Virology and Immunology, UCSF, San Francisco, CA, USA
W.Doerfler 005 - Epigenetic Modifications of HIV Proviral LTRs: Potential Targets for Cure
W.Doerfler   Authors: W.Doerfler (1), S.Weber (1), K.Kemal (2), B.Weiser (2), K.Korn (1), K.Anastos (3),
H.Burger (2)
(1) Erlangen University, Institute for Virology, Erlangen, Germany
(2) Wadsworth Center, New York State Department of Health, Albany, New-York - USA
(3) Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New-York - USA
16.00
17.00		 THREE HOT DEBATES IN HIV CARE : TIME TO VOTE!/
TROIS DÉ SUR L'ACCÈS AUX SOINS VIH : C'EST LE MOMENT DE VOTER !
First Topic : HIV Neurocognitive Disorders / Premier Sujet : Troubles Neurocognitifs Liés au VIH
  - A Real Problem / Un Vrai Problème
Magnus GISSLEN, University of Githenburg - Sweden   Magnus GISSLEN, University of Githenburg - Sweden
Hans J.STELLBRINK, Sentrum, Hamburg ICH, Hamburg - Germany   - A Past Problem / Un Problème Passè
Hans J.STELLBRINK, Sentrum, Hamburg ICH, Hamburg - Germany   Hans J.STELLBRINK, Sentrum, Hamburg ICH, Hamburg - Germany
Second Topic : PreExposure Prophylaxis / Deuxième Sujet : Prophylaxie Pré-Exposition
Mark WAINBERG, McGill University, Montreal - Canada   - A Bright Idea / Une Idée Lumineuse
Mark WAINBERG, McGill University, Montreal - Canada   Mark WAINBERG, McGill University, Montreal - Canada
  - A Danger / Un Danger
Mark NELSON, Chelsea and Westminster Hospital, London - UK   Mark NELSON, Chelsea and Westminster Hospital, London - UK
Third Topic : HIV Cure / Troisième Sujet : L'Eradication du VIH
Alain LAFEUILLADE, General Hospital, Toulon - France   - A Future / Un Futur
Alain LAFEUILLADE, General Hospital, Toulon - France   Alain LAFEUILLADE, General Hospital, Toulon - France
  - A Fantasy / Un Rêve
  Jean-Pierre ROUTY, McGill University, Montreal - Canada
17.00
18.30		  

SESSIONS COREVIH
VIEILLISSEMENT & VIH : LE CONCEPT DE FRAGILITÉ ET LES TRAVAUX DU GROUPE VISAGE

Modérateurs : Florence NICOLAI-GUERBE Déléguée Régionale PACA, SIS Association Marseille - France
Patricia ENEL Présidente du COREVIH, Hôpital de la conception, Marseille - France
Le Comité de Pilotage Ministériel et le Groupe de Travail VISAGE
    Isabelle RAVAUX, Vice-Présidente du COREVIH, Hôpital de la Conception, Marseille - France
L'Étude VISAGE 1
    Nathalie PETIT, Hôpital Sainte-Marguerite - Marseille, France
Le Concept de Fragilité Chez les Sujets VIH; Présentation de l'Étude VISAGE3
    Frédérique RETORNAZ, Centre Gérontologique Départemental 13, Marseille - France
17.00
18.30		 DISCUSSED POSTER / POSTERS COMMENTÉS
Chairpersons / Modérateurs : Pierre DELLAMONICA, University Hospital, Nice - France
  Eric JULLIAN, General Hospital, Toulon - France
  Hervé TISSOT-DUPONT, Research and Development Institute, Marseille - France
     
HIV Prevention
P002 - HIV experts on the decision to use early ART for prevention in France: Are we there yet?
Bertrand Lebouché   Authors: Bertrand Lebouché MD PhD (1), Kim Engler PhD (1), Joseph-Josy Lévy PhD (2)
Co-authors: Norbert Gilmore MD (1), Bruno Spire MD (3), Willy Rozenbaum MD (4), Jean-Pierre Routy MD (1)
(1) McGill University Health Centre, Montreal - Canada
(2) Université du Québec, Montreal - Canada
(3) INSERM-SESSTIM UMR912, Marseille - France, AIDES - France, Université d’Aix Marseille - France
(4) Hôpital Saint-Louis, Paris - France
P003 - Influx of Uncommon HIV-1 Strains From Eastern Europe and Identification of a New Unique Recombinant Strain Among Young Cypriot MSM in Cyprus
Ioanna Kousiappa   Author: Ioanna Kousiappa
Co-authors: Yiota Lazarou, Katerina M. Othonos, Johana Hezka, Leondios G. Kostrikis
University of Cyprus, Nicosia - Cyprus
P004 - Relying on Injection Drug Users to Prevent HIV in Ukraine - Follow-up Results of Peer-Driven Interventions
    Author: Oleksandra Datsenko
Co-authors: Pavlo Smyrnov, Robert Broadhead
International HIV-Aids Alliance, Kiev - Ukraine
HIV Virology
P007 - Molecular Epidemiology and Drug Resistance Prevalence of Strains from Newly Diagnosed HIV-1 Patients in Northern Greece During 2009-2010
Zoe Antoniadou   Author: Zoe Antoniadou
Co-authors: Ioanna Kousiappa, Johana Hezka, Lemonia Skoura, Simeon Metallidis, Pavlos Nikolaidis,
Nicolaos Malisiovas, Leondios G. Kostrikis
University of Cyprus, Nicosia - Cyprus
P008 - The Dual (Activating/Suppressive) Effect of Extracellular Tathiv-1 Is Driven by the Inflammatory Microenvironment Of Infected Lymphoid Foci.
    Authors: Hélène Le Buanec (1,2,3), Thomas Sené (1,2,3), Armand Bensussan (1,2,3), Robert Gallo (4), Daniel Zagury (5)
(1) INSERM U976, F-75475, Paris - France
(2) Université Paris-Diderot, Sorbonne Paris Cité, Laboratory of Immunology, Dermatology & Oncology, UMR-S 976, F-75475,Paris - France
(3) Service de dermatologie, Hôpital Saint-Louis, F-75010, Paris - France
(4) Institute of Human Virology, University of Maryland Baltimore, Maryland - USA
(5) Neovacs SA, Paris - France.
HIV Immunology
P010 - Emergence of IFN-alpha TRAIL-expressing killer pDCs (IKpDCs) as a consequence of a crosstalk with NK cells. Influence of HIV-1 infection and implication of HMGB1
Marlène Bras   Author: Marlène Bras
Co-authors: Héla Saidi, Pauline Formaglio, Marie-Thérèse Melki, Marie-Lise Gougeon
Institut Pasteur, Paris - France
P011 - Universal Mapping of Humoral Immune Response using a Versatile High-Content and High-Density Peptide Microarray
Ulf Reimer   Author: Ulf Reimer (1)
Co-authors: Nikolaus Pawlowski (2), Janina Seznec (2), Tobias Knaute (2), Paul von Hoegen (2), Holger Wenschuh (2), Dan H. Barouch (2)
(1) Jpt Peptide Technologies, Berlin - Germany
(2) Division of Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115 - USA
P014 - Alpha-1-Proteinase Inhibitor regulates CD4 lymphocyte levels and is rate limiting in HIV-1 disease
Cynthia L. Bristow   Author: Cynthia L. Bristow
Co-authors: Mariya A. Babayeva, Michelle Labrunda, Michael P. Mullen, Jose Cortes, Ronald Winston Weill Cornell Medical College, New York - USA
HIV Complications
P015 - Effective HAART Reduces the Incidence of High Grade Cervical Neoplasia in HIV Positive Women
Deborah Morris-Harris M.D   Author: Deborah Morris-Harris M.D, (1) Parkland Health and Hospital System, HIV Services, Dallas, Texas - USA
Co-authors: Charmaine Miller-Spencer M.S. (1), Clara Jones M.D. (2), Song Zhang Ph.D. (3), and James Luby M.D. (3)
(1) Parkland Health and Hospital System, HIV Services, Dallas, Texas - USA
(2) Tufts University Medical Center, Boston, Massachusetts - USA
(3) University of Texas Southwestern medical center, Dallas, Texas - USA
HIV Therapy
P017 - Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4 positive T cells from HIV-1 infected ART-treated patients
Sophie Bouchat   Author: Sophie Bouchat
Co-authors: Jean-Stéphane Gatot, Kabamba Kabeya, Laurence Colin, Stéphane De Wit, Nathan Clumeck, Olivier Lambotte, Christine Rouzioux, Olivier Rohr and Carine Van Lint
Ulb, Gosselies - Belgium
P018 - Monoclonal antibodies that recognize important functional elements of the HIV-1 integrase enzyme
Richard G. Maroun   Author: Richard G. Maroun (1)
(1) Unité de Biochimie, Faculté des Sciences, Université Saint-Joseph, CST-Mar Roukoz, Beirut - Lebanon Co-authors: Farah Ammar (2), Serge Fermandjian LBPA (2)
(2) ENS de Cachan, CNRS, Cachan - France
P019 - The orally bioavailable allosteric CXCR4 HIV-1 entry inhibitor AMD11070
Dominique Schols   Authors: Simon Fricker (1), Renee Mosi (2), Virginia Anastassova (2), Jean Labrecque (2), Rebecca Wong (2), Renato Skerlj (1), Gary Bridger (1), Dana Huskens (3) and Dominique Schols (3)
(1) Genzyme Corporation, Framingham, MA - USA
(2) Formally of AnorMED Inc., Langley, BC - Canada
(3) Rega Institute for Medical Research, University of Leuven, Leuven - Belgium
HIV Care
P021 - Rapid Cell-free CD4 Enumeration Using Whole Saliva
Cynthia L. Bristow   Author: Cynthia L. Bristow
Co-authors: Mariya A. Babayeva, Rozbeh Modarresi, Carole P. Mcarthur, Santosh Kumar, Charles Awasom, Leo Ayuk, Annette Nhinda, Paul Achu, Ronald Winston
Weill Cornell Medical College, New York - USA
Viral Hepatitis
P023 - Epidemiology of Hepatitis Delta Virus Infection in HIV-Infected Individuals in Taiwan
Hsi-Hsun Lin   Authors: Hsi-Hsun Lin, Susan Shin-Jung Lee, Ming-Lung Yu, Bo-Sean Hu, Shiou-Haur Liang, Wen-Chien Ko, Jaw-Ching Wu
Co-authors: Fan-Ceng Zheng, Chung-Hsu Lai, Jin-Long Lin E-Da Hospital, I-Shou University, Kaohsiung - Taiwan, Province of China
 
     
     
FRIDAY MAY 25, 2012 / VENDREDI 25 MAI 2012
   

The speakers reserve the right not to publish their presentation on the website www.isheid.com.
   

Les intervenants du Congrès se réservent le droit d'accepter la mise en ligne de leur présentation
sur le site www.isheid.com.
     
08.30
10.30		  

VIRAL HEPATITIS / HEPATITES VIRALES

Chairpersons / Modérateurs : Gilles HITTINGER, General Hospital, Toulon - France
   
  Jean-Claude TARDY, Croix-Rousse Hospital, Lyon - France
Hepatitis C as a Metabolic Disease / Hépatite C comme Maladie Métabolique
Patrice ANDRE, Croix-Rousse Hospital, Lyon - France     Patrice ANDRE, Croix-Rousse Hospital, Lyon - France
Challenges of New Antivirals for HCV Co-infected Patients
Les Défis des Nouveaux Anti-VHC chez les Patients Co-infectés
Vincente SORIANO, Hospital Carlos III, Madrid - Spain    Vincente SORIANO, Hospital Carlos III, Madrid - Spain
HCV Resistance / Résistance du VHC
Philippe HALFON, Ambroise Paré Hospital, Marseille - France     Philippe HALFON, Ambroise Paré Hospital, Marseille - France
What Happens after Hepatitis C Eradication? / Qu’advient-il après l’Eradication du VHC ?
Stanislas POL, Hepatology Unit, Cochin Hospital, Paris - France     Stanislas POL, Hepatology Unit, Cochin Hospital, Paris - France
P006 - Hepatitis C Virus Fails to Activate NF-kappaB Signaling in Plasmacytoid Dendritic Cells
Ruzena Stranska     Author: Ruzena Stranska
Co-authors: Jonathan Florentin, Clélia Dental, Besma Aouar, Francoise Gondois-Rey, David Durantel, Thomas F. Baumert, Jacques A. Nunes, Daniel Olive, Ivan Hirsch
Centre de Recherche en Cancérologie de Marseille, Marseille - France
P007 - HCV full-lenght genome reconstruction with sequence independent amplification combined with next generation sequencing
Bartolini Barbara     Author: Bartolini Barbara
Co-authors: Giombini Emanuela, Abbate Isabella, Visco Comandini, Ubaldo D’offizi Gianpiero, Rozera Gabriella, Selleri Marina, Ippolito Giuseppe, Capobianchi Maria Rosaria
National Institute for Infectious Diseases L. Spallanzani, Rome - Italy
P008 - Raltegravir switch improves hepatitis C transaminitis in HIV-1 and hepatitis C (HCV) co-infected individuals
Muge Cevik     Authors: Muge Cevik, Gurmit Singh
Co-authors: Laura Dickinson, Andrew Scourfield, Marta Boffito and Mark Nelson
Chelsea and Westminster Hospital, London - UK
11.00
12.30		  

MANAGING ANTIRETROVIRAL THERAPY PART II
GESTION DES TRAITEMENTS ANTIRETROVIRAUX, PARTIE II

Chairpersons / Modérateurs : Bruno LACARELLE, Timone’s Hospital, Marseille - France
   
  Robert REDFIELD, Institute of Human Virology, Baltimore - USA
Antiretroviral Generics / Les Génériques Antirétroviraux
Véronique ANDRIEU, Galenic Laboratory Faculty of Pharmacy, Marseille - France     Véronique ANDRIEU, Galenic Laboratory Faculty of Pharmacy, Marseille - France
ART without NRTIS / Thérapie Antirétrovirale sans NRTIS
Mark NELSON, Chelsea and Westminster Hospital, London - UK     Mark NELSON, Chelsea and Westminster Hospital, London - UK
Impact of HIV Minor Species and Tropism / Impact des Souches Minoritaires et du Tropisme VIH
Karin METZNER, University Hospital, Zurich - Switzerland   Karin METZNER, University Hospital, Zurich - Switzerland
     
12.30
14.00		   LUNCH SYMPOSIUM GILEAD
HIV: Chronicity’s challenges & expectations
VIH : Enjeux et perspectives de la chronicité

Chairpersons / Modérateurs : Alain LAFEUILLADE, General Hospital, Toulon - France
Roland LANDMAN, Bichat Hospital, CHU Paris - France
New STR: Treatment Paradigms Evolution / Nouveau STRs : Evolution des Paradigmes de Traitement
    Mark NELSON, Chelsea and Westminster Hospital, London - UK
Gilead HIV cure program - Search For Small Molecule Activators of Latent HIV
Le programme de guérison de Gilead - Recherche de petites molécules activantes du virus VIH latent
    Romas GELEZIUNAS, Gilead Sciences
14.00
16.00		  

EMERGING INFECTIOUS DIDISEASES / LES MALADIES INFECTIEUSES EMERGENTES

Chairpersons / Modérateurs : Philippe BROUQUI, North Hospital, Marseille - France
  Guido POLI, San Raffaele Scientific Institute, Milano - Italy
Deficits in Targeted STI-testing regarding Gay and Bisexual Men across Europe. results of the European MSM Internet Survey (EMIS)
 Défauts sur le Dépistage ciblé des IST chez les Hommes Gays et Bisexuels en Europe : Résultats de l'Enquête Européenne HSH (EMIS)
    Axel SCHMIDT, London School of Hygiene and Tropical Medecine, London - UK
A Global Virus Network and a Perspective on Viral Infections in Humans
Un Réseau Mondial Virologique et ses Perspectives chez l’Homme
    David PAUZA, Institute of Human Virology, Baltimore - USA
Human Papilloma Viruses / Les Papilloma Virus Humains
    Denise A. GALLOWAY, Fred Hutchinson Cancer Research Center, Seattle - USA
Implications of influenza Resistance /
Conséquences de la Résistance du Virus grippal
    Laurence CALATAYUD, Marseille, France
P009 - Insect cell endocytosis of chikungunya virus adapted to Aedes albopictus, a mosquito recently introduced into southern France
    Author: Christian Devaux
Co-authors: Eric Bernard, Bernard Gay, Nathalie Chazal, Laurence Briant, and Christian Devaux
Cpbs (Centre d’Études d’Agents Pathogènes et Bio. Santé), Umr5236 Cnrs, Um1, Um2, Montpellier - France
P010 - Dengue Virus-Pandemic Influenza Virus Co-infection Results in Enhanced Influenza Virus Replication Through Inhibition of Apoptosis
    Author: Thomas G. Voss, Ph.D.
Co-authors: Mei-Chun Chen, MS Gena J. Nichols, Ph.D. Somanna K. Naveen, Ph.D. Benjamin T. Bradley, BS Robert W. Cross, MPH
Tulane University, School of Medicine, New Orleans - USA
16.00
17.00		 RAPPORTEURS SUMMARY SESSION / SESSIONS DES RAPPORTEURS
Chairpersons / Modérateurs : Alain LAFEUILLADE, General Hospital, Toulon - France
  Christine Rouzioux, Necker’s Hospital, Paris - France
Epidemiology and Social Sciences Summary / Résumé Epidémiologie et Sciences Sociales
    Marie SUZAN, Inserm, Marseille - France
Virology Summary / Résumé Virologie
    Catherine TAMALET, Timone’s Hospital, M arseille - France
Immunology Summary / Résumé Immunologie
    Marie-Lise GOUGEON, Pasteur Institute, Paris - France
Clinical Summary / Résumé Clinique
    Hans J. STELLBRINK, Sentrum, Hamburg ICH, Hamburg - Germany